The tumor response to most therapeutic agents in cancer is highly unpredictable. Cancer models which can adequately represent tumor heterogeneity and predict in vivo drug sensitivity are intense areas of investigation. Recently, cancer “organoid” culture conditions have been developed to establish in vitro growth of patient-derived samples at higher efficiency and they are very promising for large scale drug screening and fundamental cancer biology research.

In this laboratory, we combine organoid culture system, bioinformatic analysis and genetic engineered mouse models to define and characterize prostate luminal progenitor cells and prostate cancer progenitor cells, to develop new biomarker of advanced prostate cancers, to establish in vitro cancer organoids at different stage, to study drug resistant with tumor microenvironment and tumor cells plasticity, to establish Chinese patients derived cancer organoid bank.